New drug targets Hard-to-Treat tumors in early trial
Disease control
Terminated
This early-phase study tested a new drug called LB4330 in 40 people with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to help the immune system attack cancer cells by targeting a protein called Claudin 18.2. The main goals were to…
Phase: PHASE1 • Sponsor: L & L Bio Co., Ltd., Ningbo, China • Aim: Disease control
Last updated Apr 24, 2026 16:09 UTC